-
1 Comment
Lupin Limited is currently in a long term uptrend where the price is trading 9.5% above its 200 day moving average.
From a valuation standpoint, the stock is 35.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Lupin Limited's total revenue rose by 3.9% to $39B since the same quarter in the previous year.
Its net income has increased by 152.5% to $4B since the same quarter in the previous year.
Finally, its free cash flow fell by 77.5% to $4B since the same quarter in the previous year.
Based on the above factors, Lupin Limited gets an overall score of 4/5.
Industry | Drug Manufacturers - Specialty & Generic |
---|---|
Sector | Healthcare |
CurrencyCode | INR |
Exchange | NSE |
ISIN | INE326A01037 |
PE Ratio | 33.34 |
---|---|
Target Price | 2272.5 |
Beta | 0.57 |
Dividend Yield | 0.4% |
Market Cap | 954B |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LUPIN.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025